Pitavastatin-attenuated cardiac dysfunction in mice with dilated cardiomyopathy via regulation of myocardial calcium handling proteins
C57BL/6 mice with dilated cardiomyopathy (DCM) were randomly divided to receive placebo or pitavastatin at a dose of 1 or 3 mg kg-1d-1. After 8 weeks treatment, mice with dilated cardiomyopathy developed serious cardiac dysfunction characterized by significantly enhanced left ventricular end-diastol...
Saved in:
Main Authors: | Hu Wei, Jiang Wen-Bing |
---|---|
Format: | Article |
Language: | English |
Published: |
Sciendo
2014-03-01
|
Series: | Acta Pharmaceutica |
Subjects: | |
Online Access: | http://www.degruyter.com/view/j/acph.2014.64.issue-1/acph-2014-0004/acph-2014-0004.xml?format=INT |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
TAB2 deficiency induces dilated cardiomyopathy by promoting mitochondrial calcium overload in human iPSC-derived cardiomyocytes
by: Wenrui Sun, et al.
Published: (2025-02-01) -
Genotype-phenotype insights of pediatric dilated cardiomyopathy
by: Ying Dai, et al.
Published: (2025-01-01) -
Outcome and prognostic value of N‐terminal pro‐brain natriuretic peptide and high‐sensitivity C‐reactive protein in mildly dilated cardiomyopathy vs. dilated cardiomyopathy
by: Jiayu Feng, et al.
Published: (2022-06-01) -
Layer-Specific Strain Analysis in Patients with Dilated Cardiomyopathy
by: Despina-Manuela Toader, et al.
Published: (2024-12-01) -
Hypocalcaemic cardiomyopathy: a description of two cases and a literature review
by: Martin Válek, et al.
Published: (2020-06-01)